<DOC>
	<DOCNO>NCT00075894</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , alanosine , use different way stop tumor cell divide stop grow die . PURPOSE : This phase I trial study side effect best dose alanosine treat patient high-grade progressive recurrent malignant glioma .</brief_summary>
	<brief_title>Alanosine Treating Patients With Progressive Recurrent Malignant Gliomas</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose alanosine ( SDX-102 ) without enzyme-inducible antiepileptic drug ( EIAEDs ) patient methylthioadenosine phosphorylase ( MTAP ) -deficient high-grade progressive recurrent malignant glioma . - Determine pharmacokinetics drug administer concurrently EIAEDs patient . OUTLINE : This open-label , nonrandomized , multicenter , dose-escalation study . Patients stratify accord concurrent anticonvulsant drug use ( drug induce hepatic metabolic enzyme vs drug cause modest induction hepatic metabolic enzyme OR anticonvulsant drug ) . Patients receive alanosine ( SDX-102 ) IV continuously 5 day . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos SDX-102 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . After completion study therapy , patient follow 1 week every 2 month thereafter . PROJECTED ACCRUAL : A total 18 patient accrue study .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Alanosine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant glioma 1 follow type : Anaplastic astrocytoma Anaplastic oligodendroglioma Glioblastoma multiforme Progressive recurrent disease prior radiotherapy without chemotherapy Lowgrade glioma progress prior radiotherapy without chemotherapy find highgrade glioma biopsy allow No 2 prior treatment regimens Measurable disease CT scan MRI Documented absence methylthioadenosine phosphorylase ( MTAP ) fix tumor specimen PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 60100 % Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin ≤ 1.5 mg/dL Transaminases ≤ 4 time upper limit normal Renal Creatinine ≤ 1.5 mg/dL Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception , , 4 week study participation Mini mental state exam score ≥ 15 No psychological sociological condition , addictive disorder , family problem would preclude study compliance No malignancy within past 5 year except curatively treat basal cell squamous cell skin cancer carcinoma situ cervix breast No concurrent serious infection medical illness would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent prophylactic growth factor ( e.g. , filgrastim [ GCSF ] sargramostim [ GMCSF ] ) Chemotherapy See Disease Characteristics At least 3 week since prior chemotherapy ( 6 week nitrosoureas ) Endocrine therapy Must maintain stable low corticosteroid regimen time baseline scan start study treatment No concurrent steroid antiemetic Radiotherapy See Disease Characteristics At least 3 month since prior radiotherapy Surgery Not specify Other Recovered prior therapy More 10 day since prior anticonvulsant drug induce hepatic metabolic enzymes No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>